Molecular Biomarkers according to Primary Tumor Location in Colorectal Cancer: Current Standard and New Insights
- 30 October 2020
- journal article
- review article
- Published by S. Karger AG in Oncology
- Vol. 99 (3), 135-143
- https://doi.org/10.1159/000510944
Abstract
According to the 2018 GLOBOCAN database, colorectal cancer is one of the most common malignancies and leading causes of cancer-related death worldwide. During the last decades, considerable progress has been made in understanding the complex pathogenetic mechanisms involved in this neoplastic disease. Due to the need to improve treatment responses and clinical outcomes of colorectal cancer patients, the identification of new molecular biomarkers became a crucial spot in clinical oncology. As biological indicators of a specific pathological or physiological process, molecular markers play a central role in cancer detection, diagnosis, outcome prediction, and treatment choice. Considering the existing evidence that malignancies originating from distinct colonic regions behave differently, it is clear that specific biomarkers can be associated to right- or left-sided colon carcinomas, reflecting the distinct molecular signatures of these different tumor entities. The aim of this review is to summarize the main differences among tumors arising from proximal and distal colon in terms of current and emerging biomarkers.Keywords
This publication has 47 references indexed in Scilit:
- BRAF codons 594 and 596 mutations identify a new molecular subtype of metastatic colorectal cancer at favorable prognosisAnnals of Oncology, 2015
- Aberrant TET1 Methylation Closely Associated with CpG Island Methylator Phenotype in Colorectal CancerCancer Prevention Research, 2015
- Erratum: Clonal evolution and resistance to EGFR blockade in the blood of colorectal cancer patientsNature Medicine, 2015
- A clinicopathological analysis of KISS1 and KISS1R expression in colorectal cancerAPMIS, 2015
- Predictive role of BRAF mutations in patients with advanced colorectal cancer receiving cetuximab and panitumumab: A meta-analysisEuropean Journal of Cancer, 2015
- Mismatch Repair Status and BRAF Mutation Status in Metastatic Colorectal Cancer Patients: A Pooled Analysis of the CAIRO, CAIRO2, COIN, and FOCUS StudiesClinical Cancer Research, 2014
- BRAFV600E Mutation Analysis in Patients with Metastatic Colorectal Cancer (mCRC) in Daily Clinical Practice: Correlations with Clinical Characteristics, and Its Impact on Patients’ OutcomePLOS ONE, 2013
- Prognostic Impact of Deficient DNA Mismatch Repair in Patients With Stage III Colon Cancer From a Randomized Trial of FOLFOX-Based Adjuvant ChemotherapyJournal of Clinical Oncology, 2013
- BRAF mutation is a powerful prognostic factor in advanced and recurrent colorectal cancerBritish Journal of Cancer, 2011
- KRAS Mutation in Stage III Colon Cancer and Clinical Outcome Following Intergroup Trial CALGB 89803Clinical Cancer Research, 2009